Read on the GuardianThe $3 Revolution: How Generic Semaglutide Could Transform Global Health
New research reveals that semaglutide, the active ingredient in weight-loss drugs Ozempic and Wegovy, could be manufactured for as little as $3 per month. With patents expiring in key countries and no patents filed in 160 nations, this breakthrough opens the door to potentially treating millions with diabetes and obesity in low- and middle-income countries. The World Health Organization's designation of semaglutide as an essential medicine underscores its importance, but high prices have limited access until now.
The global obesity and diabetes epidemics represent one of the most pressing public health challenges of our time, affecting over a billion people worldwide. For years, breakthrough medications like semaglutide—marketed as Ozempic for diabetes and Wegovy for obesity—have offered hope but remained financially out of reach for most of the world's population. Now, groundbreaking research suggests this could change dramatically. According to a new study published as a pre-print, semaglutide could be mass-produced for just $3 per month in its injectable form, potentially transforming access to this essential medicine across 160 countries.
The Global Access Opportunity
The research, conducted by scientists including Dr. Andrew Hill of Liverpool University, reveals a remarkable pricing breakthrough. The $3 monthly cost for injectable semaglutide represents a fraction of current market prices, which hover around $200 in the United States and £120 in the United Kingdom. Even newer oral formulations could be produced for approximately $16 monthly. This dramatic cost reduction stems from analyzing shipment records of key ingredients from 2024 and 2025, using methodology that has accurately predicted generic medicine prices for HIV, hepatitis C, and cancer drugs in the past.
What makes this development particularly significant is the patent landscape. Core patents on semaglutide are set to expire in 10 countries this year, including major markets like Brazil, China, India, South Africa, Turkey, Mexico, and Canada beginning March 21st. More importantly, researchers identified 150 additional countries where patents were never filed, encompassing most of Africa. Together, these 160 nations are home to 69% of people with type 2 diabetes and 84% of those living with obesity worldwide.
Essential Medicine Designation and Historical Precedent
The World Health Organization's decision in September last year to designate semaglutide as an essential medicine highlighted its critical importance while simultaneously underscoring the access problem. Global health leaders warned that high prices were creating insurmountable barriers, particularly in low- and middle-income countries where obesity and diabetes rates are rising fastest due to dietary shifts toward westernized patterns and increasingly sedentary lifestyles.
Professor François Venter from Witwatersrand University in Johannesburg draws a powerful parallel to previous pharmaceutical successes: "Drugs to treat HIV, TB, malaria and hepatitis are available in low- and middle-income countries for prices close to the cost of production, saving millions of lives while allowing generic companies to make sufficient profit to ensure sustainable supply. We can repeat this medical success story for semaglutide." This historical precedent suggests that coordinated global health strategies could successfully implement widespread semaglutide access.
Implementation Challenges and Systemic Considerations
While the pricing breakthrough offers tremendous promise, researchers caution that cheaper treatments alone won't solve the complex obesity epidemic. The structural drivers—including food insecurity, poverty, urbanization, and commercial food environments—require comprehensive policy responses. Dr. Nomathemba Chandiwana, chief scientific officer at South Africa's Desmond Tutu Health Foundation, notes that approximately 27% of adults worldwide meet criteria for semaglutide treatment, with most living in low- and middle-income countries where access has been extremely limited.
The key question now revolves around how health systems will responsibly integrate these medications into broader obesity and diabetes care frameworks. Obesity's connections to heart disease, stroke, cancer, and other conditions mean that semaglutide access must be part of holistic healthcare approaches. With 3.7 million annual deaths attributed to excess weight and diabetes rates skyrocketing from 200 million in 1990 to 830 million in 2022, the stakes couldn't be higher.
The Path Forward
The research findings align with earlier work by Médecins Sans Frontières in 2024, which similarly concluded that diabetes drugs including semaglutide could be manufactured and sold much more affordably. As patents begin expiring this month in key countries, the stage is set for what could become one of the most significant global health interventions of the decade.
Success will require coordinated policies, strategic procurement planning, and healthcare system strengthening to ensure that reduced prices translate into actual patient access. The potential to repeat the success stories of HIV and malaria treatment accessibility offers a hopeful template, but realizing this vision will demand sustained commitment from governments, international organizations, and pharmaceutical manufacturers alike.
